NCT04421560View on ClinicalTrials.gov

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 1, 2020

Primary Completion Date

December 5, 2025

Study Completion Date

January 5, 2026

Conditions
Primary Central Nervous System LymphomaRecurrent CancerRefractory CancerRelapsed Cancer
Interventions
DRUG

Ibrutinib

Capsule, taken by mouth daily

DRUG

Pembrolizumab

Given as an intravenous injection through a vein (IV) every 3 weeks

DRUG

Rituximab

Given as infusion into a vein (intravenous, IV)

Trial Locations (4)

10032

WITHDRAWN

Columbia University Medical Center, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

02115

RECRUITING

Dana Farber Cancer Institute, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER